ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

MYGN vs ACHV // RETURN ON INVESTED CAPITAL (ROIC)

Myriad Genetics Inc. (NASDAQ) VS. Achieve Life Sciences Inc. (NASDAQ) • 15-METRIC TALLY: MYGN 3 — ACHV 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MYGN VS. ACHV) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC MYGN ACHV SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 69.90% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield 0.28% -6.69% +6.97 MYGN /fcf-yield <GO>
Operating Margin -47.00% — — TIE /operating-margins <GO>
Net Profit Margin -44.40% — — TIE /net-margins <GO>
Revenue Growth (YoY) -1.60% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 6/9 2/9 +4.00 MYGN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 72.7 46.4 +26.24 MYGN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $638.0M $739.9M -$101.9M ACHV /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR MYGN REV ACHV REV MYGN GROSS % ACHV GROSS % MYGN FCF ACHV FCF
FY 2025 $824.5M $0 69.9% — $1.8M -$49.5M
FY 2024 $837.6M $0 69.9% — -$8.7M -$29.8M
FY 2023 $753.2M $0 — — -$110.9M -$24.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MYGN // BETA —
ACHV // BETA —